| Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies WMH Zijlstra, JM Douwes, EB Rosenzweig, S Schokker, U Krishnan, ... Journal of the American College of Cardiology 63 (20), 2159-2169, 2014 | 167 | 2014 |
| Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT) T Van Den Ende, NC De Clercq, MI van Berge Henegouwen, SS Gisbertz, ... Clinical Cancer Research 27 (12), 3351-3359, 2021 | 160 | 2021 |
| Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma M Strijker, EC Soer, M de Pastena, A Creemers, A Balduzzi, JJ Beagan, ... International journal of cancer 146 (5), 1445-1456, 2020 | 82 | 2020 |
| Phase II Feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2–positive … CI Stroes, S Schokker, A Creemers, RJ Molenaar, MCCM Hulshof, ... Journal of Clinical Oncology 38 (5), 462, 2020 | 56 | 2020 |
| Quality of life during palliative systemic therapy for esophagogastric cancer: systematic review and meta-analysis JJ Van Kleef, E Ter Veer, HG Van Den Boorn, S Schokker, LL Ngai, ... JNCI: Journal of the National Cancer Institute 112 (1), 12-29, 2020 | 47 | 2020 |
| Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis E Ter Veer, JJ van Kleef, S Schokker, SO van der Woude, M Laarman, ... European Journal of Cancer 103, 214-226, 2018 | 30 | 2018 |
| A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial. T van den Ende, NC de Clercq, MI van Berge Henegouwen, SS Gisbertz, ... Journal of Clinical Oncology 37 (15_suppl), 4045-4045, 2019 | 24 | 2019 |
| Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer MJM van Velzen, A Creemers, T van den Ende, S Schokker, S Krausz, ... Gastric Cancer 25 (5), 906-915, 2022 | 16 | 2022 |
| Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab S Schokker, F Fusetti, F Bonardi, RJ Molenaar, RAA Mathôt, ... MAbs 12 (1), 1795492, 2020 | 14 | 2020 |
| Phase I dose escalation study with expansion cohort of the addition of nab-paclitaxel to capecitabine and oxaliplatin (CapOx) as first-line treatment of metastatic … S Schokker, SO van der Woude, JJ van Kleef, DJ van Zoen, ... Cancers 11 (6), 827, 2019 | 6 | 2019 |
| Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The … S Schokker, RJ Molenaar, SL Meijer, RAA Mathot, S Van der Woude, ... Journal of Clinical Oncology 36 (15_suppl), 4057-4057, 2018 | 6 | 2018 |
| Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT) Clin Cancer Res. 2021; 27 … T van den Ende, NC de Clercq, MI van Berge Henegouwen, SS Gisbertz, ... DOI: https://doi. org/10.1158/1078-0432. CCR-20-4443. PMID: https://www …, 0 | 6 | |
| A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT) CI Stroes, S Schokker, M Khurshed, SO van der Woude, RAA Mathôt, ... Therapeutic advances in medical oncology 14, 17588359221109196, 2022 | 3 | 2022 |
| A phase II study demonstrates no feasibility of adjuvant treatment with six cycles of S-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ERCC1 as biomarker for … CI Stroes, S Schokker, RJ Molenaar, RAA Mathôt, MF Bijlsma, ... Cancers 13 (4), 839, 2021 | 3 | 2021 |
| Regorafenib in combination with paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): A phase Ib trial with expansion cohort M Khurshed, CI Stroes, S Schokker, S Van Der Woude, R Mathôt, ... Annals of Oncology 30, v307, 2019 | 3 | 2019 |
| Children with pulmonary arterial hypertension (PAH) associated with congenital heart disease are treated less intensively with PAH-targeted drugs compared to children with … WMH Zijlstra, JM Douwes, EB Rosenzweig, S Schokker, U Krishnan, ... European Heart Journal 34 (suppl_1), P304, 2013 | 3 | 2013 |
| Intestinal and tumor microbiome analysis combined with metabolomics of the anti-PD-L1 phase II PERFECT trial for resectable esophageal adenocarcinoma. NC de Clercq, T van den Ende, A Prodan, MI van Berge Henegouwen, ... Journal of Clinical Oncology 38 (15_suppl), 4556-4556, 2020 | 2 | 2020 |
| Prognostic and predictive factors for overall survival (OS) in metastatic esophagogastric cancer (EGC): A meta-analysis. E Ter Veer, JJ Van Kleef, S Schokker, S Van Der Woude, M Laarman, ... Journal of Clinical Oncology 35 (15_suppl), 4048-4048, 2017 | 2 | 2017 |
| Beyond first line treatment for advanced esophagogastric adenocarcinoma (EGAC): A phase 1 dose escalation study of regorafenib (Reg) combined with paclitaxel (PTX)(REPEAT study) S Schokker, SO Van der Woude, RAA Mathot, MF Bijlsma, ... Annals of Oncology 28, v234, 2017 | 1 | 2017 |
| Transatlantic survival differences in pediatric pulmonary hypertension: Clues to A better understanding of disease characteristics and treatment WMH Zijlstra, JM Douwes, E Rosenzweig, S Schokker, U Krishnan, ... B64. MANAGEMENT OF PULMONARY HYPERTENSION, A3285-A3285, 2013 | 1 | 2013 |
